Your browser doesn't support javascript.
loading
Reproducibility of the Oxford classification of immunoglobulin A nephropathy, impact of biopsy scoring on treatment allocation and clinical relevance of disagreements: evidence from the VALidation of IGA study cohort.
Bellur, Shubha S; Roberts, Ian S D; Troyanov, Stéphan; Royal, Virginie; Coppo, Rosanna; Cook, H Terence; Cattran, Daniel; Arce Terroba, Yolanda; Asunis, Anna Maria; Bajema, Ingeborg; Bertoni, Elisabetta; Bruijn, Jan A; Cannata-Ortiz, Pablo; Casartelli, Donatella; Maria Di Palma, Anna; Ferrario, Franco; Fortunato, Mirella; Furci, Luciana; Gakiopoulou, Hariklia; Galesic Ljubanovic, Danica; Giannakakis, Konstantinos; Gomà, Montserrat; Gröne, Hermann-Josef; Gutiérrez, Eduardo; Asma Haider, S; Honsova, Eva; Ioachim, Elli; Karkoszka, Henryk; Kipgen, David; Maldyk, Jagoda; Mazzucco, Gianna; Orhan, Diclehan; Ozluk, Yasemin; Pantzaki, Afroditi; Perkowska-Ptasinska, Agnieszka; Riispere, Zivili; Soderberg, Magnus P; Steenbergen, Eric; Stoppacciaro, Antonella; Sundelin Von Feilitzen, Birgitta; Tardanico, Regina.
Afiliação
  • Bellur SS; Oxford University Hospitals, Oxford, UK.
  • Roberts ISD; Oxford University Hospitals, Oxford, UK.
  • Troyanov S; Hôpital du Sacré-Coeur de Montréal, Montreal, Canada.
  • Royal V; Hôpital Maisonneuve-Rosemont, Montreal, Canada.
  • Coppo R; City of the Health and the Science of Turin Health Agency, Regina Margherita Children's Hospital, Turin, Italy.
  • Cook HT; Imperial College, Hammersmith Hospital, London, UK.
  • Cattran D; Toronto General Hospital, University Health Network, Toronto, Ontario, Canada.
  • Arce Terroba Y; Nephrology, Fundacion Puigvert, Barcelona, Spain.
  • Asunis AM; Pathology, G. Brotzu Hospital, Cagliari, Italy.
  • Bajema I; Leiden University Medical Center, Leiden, The Netherlands.
  • Bertoni E; Careggi-University Hospital, Florence, Italy.
  • Bruijn JA; Leiden University Medical Center, Leiden, The Netherlands.
  • Cannata-Ortiz P; ISS-Fundación Jiménez Díaz, Madrid, Spain.
  • Casartelli D; Alessandro Manzoni Hospital, Lecco, Italy.
  • Maria Di Palma A; University of Bari, Bari, Italy.
  • Ferrario F; Nephropathology, San Gerardo Hospital, Monza, Italy.
  • Fortunato M; Pathology, S. Croce Hospital, Cuneo, Italy.
  • Furci L; Pathology, Policlinic of Modena and Reggio Emilia, Modena, Italy.
  • Gakiopoulou H; National and Kapodistrian University of Athens, Greece, Athens, Greece.
  • Galesic Ljubanovic D; School of Medicine, University Hospital Dubrava, University of Zagreb, Zagreb, Croatia.
  • Giannakakis K; Sapienza University of Rome, Rome, Italy.
  • Gomà M; Hospital Universitari de Bellvitge, Barcelona, Spain.
  • Gröne HJ; German Cancer Research Center, INF 280, Heidelberg, Germany.
  • Gutiérrez E; Nephrology Department, University Hospital October 12, Madrid, Spain.
  • Asma Haider S; Pathology, Leicester General Hospital, Leicester, UK.
  • Honsova E; Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
  • Ioachim E; Nephrology, Medical School University of Ioannina, Ioannina, Greece.
  • Karkoszka H; Medical University of Silesia, Katowice, Poland.
  • Kipgen D; Pathology, Western Infirmary Glasgow, Glasgow, UK.
  • Maldyk J; Medical University of Warsaw, Warsaw, Poland.
  • Mazzucco G; Pathology, University of Turin, Italy.
  • Orhan D; Hacettepe University Institute of Children's Health, Ankara, Turkey.
  • Ozluk Y; Istanbul University, Istanbul, Turkey.
  • Pantzaki A; Hippokration General Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece.
  • Perkowska-Ptasinska A; Transplantation Medicine and Nephrology, Warsaw Medical University, Warsaw, Poland.
  • Riispere Z; Pathology, Tartu University Clinics, Tartu, Estonia.
  • Soderberg MP; Pathology, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Gothenburg, Sweden.
  • Steenbergen E; Nephropathology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
  • Stoppacciaro A; Pathology S. Andrea Hospital, Rome, Italy.
  • Sundelin Von Feilitzen B; Karolinska Institute, Stockholm, Sweden.
  • Tardanico R; Spedali Civili di Brescia, Brescia, Italy.
Nephrol Dial Transplant ; 34(10): 1681-1690, 2019 10 01.
Article em En | MEDLINE | ID: mdl-30561721
ABSTRACT

BACKGROUND:

The VALidation of IGA (VALIGA) study investigated the utility of the Oxford Classification of immunoglobulin A nephropathy (IgAN) in 1147 patients from 13 European countries. Methods. Biopsies were scored by local pathologists followed by central review in Oxford. We had two distinct

objectives:

to assess how closely pathology findings were associated with the decision to give corticosteroid/immunosuppressive (CS/IS) treatments, and to determine the impact of differences in MEST-C scoring between central and local pathologists on the clinical value of the Oxford Classification. We tested for each lesion the associations between the type of agreement (local and central pathologists scoring absent, local present and central absent, local absent and central present, both scoring present) with the initial clinical assessment, as well as long-term outcomes in those patients who did not receive CS/IS.

RESULTS:

All glomerular lesions (M, E, C and S) assessed by local pathologists were independently associated with the decision to administer CS/IS therapy, while the severity of tubulointerstitial lesions was not. Reproducibility between local and central pathologists was moderate for S (segmental sclerosis) and T (tubular atrophy/interstitial fibrosis), and poor for M (mesangial hypercellularity), E (endocapillary hypercellularity) and C (crescents). Local pathologists found statistically more of each lesion, except for the S lesion, which was more frequent with central review. Disagreements were more likely to occur when the proportion of glomeruli affected was low. The M lesion, assessed by central pathologists, correlated better with the severity of the disease at presentation and discriminated better with outcomes. In contrast, the E lesion, evaluated by local pathologists, correlated better with the clinical presentation and outcomes when compared with central review. Both C and S lesions, when discordant between local and central pathologists, had a clinical phenotype intermediate to double absent lesions (milder disease) and double present (more severe).

CONCLUSION:

We conclude that differences in the scoring of MEST-C criteria between local pathologists and a central reviewer have a significant impact on the prognostic value of the Oxford Classification. Since the decision to offer immunosuppressive therapy in this cohort was intimately associated with the MEST-C score, this study indicates a need for a more detailed guidance for pathologists in the scoring of IgAN biopsies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variações Dependentes do Observador / Modelos Estatísticos / Seleção de Pacientes / Glomerulonefrite por IGA Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Variações Dependentes do Observador / Modelos Estatísticos / Seleção de Pacientes / Glomerulonefrite por IGA Idioma: En Ano de publicação: 2019 Tipo de documento: Article